Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius Buys 10,000 Shares

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction dated Friday, March 7th. The shares were purchased at an average price of $10.90 per share, with a total value of $109,000.00. Following the transaction, the director now directly owns 101,459 shares of the company's stock, valued at approximately $1,105,903.10. The trade was a 10.93 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Tuesday, March 11th, Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock. The shares were purchased at an average price of $10.20 per share, with a total value of $102,000.00.

Elanco Animal Health Trading Up 1.5 %

ELAN stock traded up $0.16 during mid-day trading on Friday, reaching $10.47. 4,680,857 shares of the stock traded hands, compared to its average volume of 4,670,565. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 52-week low of $10.03 and a 52-week high of $18.80. The company has a market cap of $5.18 billion, a P/E ratio of 26.16, a P/E/G ratio of 2.50 and a beta of 1.44. The stock's fifty day moving average is $11.49 and its 200-day moving average is $12.80.

Remove Ads

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health's quarterly revenue was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 earnings per share. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

ELAN has been the subject of several research analyst reports. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus cut their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. Finally, Barclays cut their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $15.17.

Institutional Trading of Elanco Animal Health

A number of hedge funds have recently made changes to their positions in the stock. Commerce Bank lifted its position in shares of Elanco Animal Health by 2.2% in the third quarter. Commerce Bank now owns 35,114 shares of the company's stock worth $516,000 after purchasing an additional 741 shares in the last quarter. Hillsdale Investment Management Inc. lifted its position in shares of Elanco Animal Health by 2.1% in the fourth quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock worth $524,000 after purchasing an additional 900 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Elanco Animal Health by 0.8% in the fourth quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock worth $1,737,000 after purchasing an additional 1,166 shares in the last quarter. MTM Investment Management LLC lifted its position in shares of Elanco Animal Health by 9.3% in the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock worth $172,000 after purchasing an additional 1,200 shares in the last quarter. Finally, M&T Bank Corp lifted its position in shares of Elanco Animal Health by 5.9% in the third quarter. M&T Bank Corp now owns 26,407 shares of the company's stock worth $388,000 after purchasing an additional 1,464 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.